About ImmunoSolv

ImmunoSolv is a vibrant, young biotechnology company born out of world-class science at the University of Edinburgh and University of Aberdeen, Scotland, UK. We specialize in the development of enabling technologies aimed at improving the quality of all animal cells in vitro – including cells for therapy – through detection and removal of dead cells. We currently have a portfolio of products available (our Dead-Cert^® range) that are designed to improve quality of cells for R&D purposes and will shortly launch GMP-compliant products to be applied to improving the quality and productivity of cells and proteins for therapeutic purposes. We also offer services in diagnostic or therapeutic antibody development and have long-established expertise in production of high-quality antibodies, especially to non-immunogenic molecules. We are combining our expertise in cell death, immunology and immunotechnology to produce new therapeutics in cancer and inflammatory disease.

Download an Executive Summary of our business here (PDF, 2.03MB)